HLS Therapeutics appoints Linda Maxwell, Mark DeLong as independent directors

• HLS Therapeutics appointed Linda Maxwell, M.D. and Mark DeLong as independent directors, replacing Kyle Dempsey and Christine Elliott.
• Board size remains eight directors, including six independent directors.
• Maxwell, a director at ImmunityBio and United Therapeutics, joins the Audit Committee.
• DeLong, CEO of Arrakis Therapeutics and former Apellis chief business and strategy officer, joins the Compensation and Governance Committee.
• Elliott stepped down from the board, returning as a consultant focused on healthcare policy and government relations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HLS Therapeutics Inc. published the original content used to generate this news brief via CNW (Ref. ID: 202610010700CANADANWCANADAPR_C7320) on October 01, 2026, and is solely responsible for the information contained therein.